Supporting that alanine supplementation competes with glutamine for SLC38A2, the addition of glutamine or ectopic expression of SLC38A2 rescued SMARCA4/2-deficient cancer cells from growth suppression and OXPHOS inhibition caused by alanine treatment (Fig. 5h, Supplementary Fig. 8d–n). Here, SLC38A2 is linked to cancer.